FDA Reconsidering Medstone STS Lithotripter PMA For Gallstone Treatment
This article was originally published in The Gray Sheet
Executive Summary
Medstone International is developing a protocol for a post-approval clinical study of the firm's STS lithotripter for gallstone treatment as FDA begins to revisit its August 1998 decision to reject the firm's premarket approval application.
You may also be interested in...
Medstone STS Lithotripter Approvable For Gallstone Treatment - FDA Panel
Medstone International should conduct post-approval studies of its STS lithotripter in combination with Novartis' Actigall (ursodiol) anti-gallstone drug to fragment biliary stones, FDA's Gastroenterology and Urology Devices Panel recommended April 30.
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.